{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:08:45Z","timestamp":1783487325851,"version":"3.55.0"},"reference-count":18,"publisher":"FapUNIFESP (SciELO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>OBJECTIVE: To report the use of sodium diclofenac, an antagonist of PPAR-gamma and cyclooxigenase-2 (COX-2) inhibitor in the treatment of mild to moderate Graves' ophthalmopathy. SUBJECTS AND METHODS: Thirteen patients with clinical activity score (CAS) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 \u00b1 3.4) with oral sodium diclofenac, 50 mg every 12 hours. RESULTS: Extra-ocular muscle restriction and CAS improved significantly, p = 0.003 and = 0.004, respectively. Ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. No recurrence was found after interruption of treatment. CONCLUSIONS: Treatment of moderate Graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. Like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study.<\/jats:p>","DOI":"10.1590\/s0004-27302011000900004","type":"journal-article","created":{"date-parts":[[2012,1,7]],"date-time":"2012-01-07T00:48:00Z","timestamp":1325897280000},"page":"692-695","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study"],"prefix":"10.1590","volume":"55","author":[{"given":"Walter","family":"Bloise","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia Yuri","family":"Mimura","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janete","family":"Moura","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilian","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy, mechanism of disease","volume":"362","author":"Bahn RS","year":"2010","journal-title":"Review. N Engl J Med."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/thy.2007.0406","article-title":"Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy, animal models and translation to human clinical trials","volume":"18","author":"Paul Banga J","year":"2008","journal-title":"Thyroid."},{"key":"ref3","first-page":"210","article-title":"Novel treatment modalities for Graves' orbitopathy","volume":"2","author":"Bartalena L","year":"2007","journal-title":"Pediatric Endocrinol Rev Suppl."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/105072503322401032","article-title":"Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose\/connective tissues is increased during the active stage of Graves' ophthalmopathy","volume":"13","author":"Mimura LY","year":"2003","journal-title":"Thyroid."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.1.02280","article-title":"Expression of cyclooxigenase-2 in orbital fibroadipose connective tissues of Graves\u2019 ophthalmopathy patients","volume":"155","author":"Konuk EBY","year":"2006","journal-title":"Eur J Endocrinol."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/thy.2007.0028","article-title":"Cox-2 and SCD, markers of inflamation and adipogenesis, are related to disease activity in Graves\u2019 ophthalmopathy","volume":"17","author":"Vondriichova T","year":"2007","journal-title":"Thyroid."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/mol.61.1.7","article-title":"Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling","volume":"61","author":"Adamson DJA","year":"2002","journal-title":"Mol Pharmacol."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1185\/03007995.2010.486301","article-title":"Diclofenac: an update on its mechanism of action and safety profile","volume":"26","author":"Gan TJ","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy","volume":"18","author":"Bartalena L","year":"2008","journal-title":"Thyroid."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves\u2019 ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El Fassi D","year":"2006","journal-title":"Thyroid."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab","volume":"156","author":"Salvi M","year":"2007","journal-title":"An open study. Eur J Endocrinol."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etarnecept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens D","year":"2005","journal-title":"Eye."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","article-title":"Infiximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy","volume":"24","author":"Durrani OM","year":"2005","journal-title":"Orbit."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occuring with anti-tumor necrosis factor- (alpha) therapy","volume":"66","author":"Simsek J","year":"2007","journal-title":"Am Rheum Dis."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1210\/jc.2002-020987","article-title":"Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thyazolidinedione use","volume":"88","author":"Starkey K","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2415-7-8","article-title":"Thiazolidinedione induced thyroid associated orbitopathy","volume":"7","author":"Lee S","year":"2007","journal-title":"BMC Ophthalmol."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-Deoxy delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma","volume":"83","author":"Forman BM","year":"1995","journal-title":"Cell."},{"key":"ref18","first-page":"286","article-title":"Long-term indomethacin treatment of ophthalmopathies after Basedow disease in general practice","volume":"181","author":"Amemiya T","year":"1982","journal-title":"Klin Monbl Augenheilkd."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v55n9\/04.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T23:30:51Z","timestamp":1495841451000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302011000900004&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0004-27302011000900004"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302011000900004","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}